A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study
Open Access
- 1 December 1997
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 8 (12) , 1213-1220
- https://doi.org/10.1023/a:1008270307264
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- High‐dose epirubicin and r‐met‐hu G‐CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group studyMedical and Pediatric Oncology, 1995
- Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancerEuropean Journal Of Cancer, 1994
- Drugs ten years later: EpirubicinAnnals of Oncology, 1993
- Escalating drug delivery in cancer chemotherapy: A review of concepts and practice – Part 1Annals of Oncology, 1993
- High-Dose Epirubicin as a Single Agent in the Treatment of Patients with Advanced Breast CancerTumori Journal, 1991
- Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.Journal of Clinical Oncology, 1986
- Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction proceduresCancer Chemotherapy and Pharmacology, 1983
- Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research.BMJ, 1983
- Reporting results of cancer treatmentCancer, 1981
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981